NRx Pharmaceuticals (NRXP)
(Delayed Data from NSDQ)
$2.60 USD
+0.02 (0.78%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $2.65 +0.05 (1.92%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Price, Consensus and EPS Surprise
NRXP 2.60 +0.02(0.78%)
Will NRXP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NRXP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NRXP
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
NRXP: What are Zacks experts saying now?
Zacks Private Portfolio Services
NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for April 4th
Pick These Top-Ranked Stocks to Deck Up Your Christmas Tree
Other News for NRXP
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing
NRx Pharmaceuticals to proceed with two new NDAs in 2024
NRX Pharmaceuticals Faces Agreement Termination, Eyes Accelerated Approval
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors